EUCTR2008-002646-35-BE进行中（未招募）不适用
A prospective phase 1, single-dose, open-label, multi-centre clinical trial to evaluate the pharmacokinetics and safety of M0003 in young children aged between 1 and 36 months.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Movetis NV
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Boy or girl, aged 30 days up to 36 months at Visit 1 (gestational age at least 40 weeks).
- •2. Child hospitalized or in day care and requiring an iv catheter
- •3. Functional GI system (e.g. no ileus, no diarrhea)
- •4. Parents or legal representative voluntarily signed written Informed Consent Form (ICF) in accordance with the regional laws or regulations, before the first trial related activity.
- •5. Parents or legal representative are willing to adhere to all trial requirements.
- •If the results of the biochemistry, haematology, or urinalysis tests are not within the laboratory's reference ranges, the subject can be included only on condition that the investigator judges that the deviations are not clinically significant. This should be clearly recorded in the Case Report Form (CRF).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Congenital abnormalities of the GI tract, heart, or liver.
- •3. Serious concurrent systemic disorders, including chronic renal disease or chronic liver disease.
- •4. Subject with clinically significant abnormal laboratory results at Visit 1.
- •5. Significant haematemesis or apparent life-threatening events (ALTEs).
- •6. Treatment with a histamine-2-receptor antagonist (H2RA), antacid, sucralfate, prostaglandin, or motility agent within 3 days prior to Visit 2.
- •7. Treatment with a proton pump inhibitor or potent CYP3A4 inhibitor within 7 days before Visit 2.
- •8. QTcB > or = 460 ms (at Visit 1 or 2), congenital prolonged QT syndrome, prolonged QTc secondary to diabetes mellitus, or family history of prolonged QT syndrome.
- •9. Significant arrhythmias, including ventricular arrhythmias, 2nd or 3rd degree atrioventricular block, congestive heart failure or ischaemic heart disease, ventricular tachycardia, and torsade de pointes.
- •10. History of significant arrhythmias in other siblings from the same parents or in the parents.
- •11. History of sudden infant death in other sibling from the same parents and/or history of a serious ALTE in the subject or other sibling from the same parents.
- •12. Any condition that, in the opinion of the Investigator(s) would complicate or compromise the trial (e.g., human immunodeficiency virus [HIV] infection, gastroduodenal ulcer, …) or the well-being of the subject, or evidence of any clinically relevant pathology that could interfere with the trial results or put the subject’s safety at risk.
- •13. Any condition in the parent/guardian/caregiver or legal representative associated with poor subject compliance (e.g., substance abuse) or inability of the parent/guardian/caregiver or legal representative to return with the child for scheduled visits.
- •14. Participation in any other investigational new drug trial and/or cohort trial.
- •15. Subject is a first or second line relative of the Investigator(s).
研究者
相似试验
进行中（未招募）
不适用
A prospective phase 1, single-dose, open-label, multi-centre clinical trial to evaluate the pharmacokinetics and safety of M0003 in young children aged between 1 and 36 months.Intended indication for product under development: Infant gastro-oesophageal reflux disease (GORD)MedDRA version: 9.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2008-002646-35-NLMovetis NV20
进行中（未招募）
1 期
A prospective phase 1, single-dose, open-label, multi-centre clinical trial to evaluate the pharmacokinetics and safety of M0003 in young children aged between 1 and 36 months.Intended indication for product under development: Infant gastro-oesophageal reflux disease (GORD)MedDRA version: 9.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2008-002646-35-GBMovetis NV20
已完成
1 期
A study to measure how much of the study drug GDC-6036 is absorbed and the effect of food on absorption in healthy participantsISRCTN10450075Genentech, Inc.18
已完成
1 期
A study to investigate the effects of food and administration of different forms of mavodelpar on the safety and concentration of mavodelpar in the bloodHealthy VolunteersISRCTN85791974Reneo Pharma Ltd (United Kingdom)32
已完成
不适用
A Phase I, open-label, randomized, single-dose, two-way crossover study to compare the relative bioavailability of GLPG2737 given as a capsule formulation and an oral suspensioCystic fibrosismucoviscidosisthick mucus disease10027664NL-OMON45861Galapagos NV12